Skip to main
CRMD
CRMD logo

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. has demonstrated strong financial performance with a reported quarterly revenue of over $85 million for DefenCath, indicating significant year-over-year growth that has surpassed both expectations and previous guidance. The company has raised its pro-forma revenue guidance for 2025 to over $375 million, reflecting confidence in the continued adoption of DefenCath among dialysis practices and successful integration of recently acquired assets from Melinta. With projected revenues for Q3 2025 estimated at $55 million, complemented by recent forecast improvements, the outlook for sustained growth and cash flow enhancement remains robust.

Bears say

Cormedix Inc. demonstrates several fundamental weaknesses contributing to a negative outlook on its stock. The company is projected to continue incurring net losses until at least the product approval and commercialization of DefenCath, creating uncertainty regarding its financial sustainability. Additionally, significant risks are present, including competition from established heparin solutions, potential concentration risk with a single customer, and unclear future pricing strategies post-TDAPA, all of which could severely impact the company's valuation and market positioning.

CorMedix (CRMD) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 6 analysts, CorMedix (CRMD) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.